Nephrology Dialysis Transplantation

Papers
(The H4-Index of Nephrology Dialysis Transplantation is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA266
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey142
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls114
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease104
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)88
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients83
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice81
Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study80
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis79
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)73
Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism72
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial70
Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?69
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)65
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study59
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disea59
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone57
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAP55
Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study55
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort54
Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management54
Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players48
The impact of chronic kidney disease Stages 3–5 on pregnancy outcomes47
At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis44
The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria44
Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study42
Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa39
Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-1939
Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?38
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results37
Urine proteomics for prediction of disease progression in patients with IgA nephropathy36
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients36
What should European nephrology do with the new CKD-EPI equation?35
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?35
Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the 35
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases35
0.093019008636475